Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEMD NYSE:ALUR NASDAQ:SURG NASDAQ:VVOS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEMDAethlon Medical$2.02+6.3%$2.22$1.36▼$27.40$2.98M1.491.70 million shs382,356 shsALURAllurion Technologies$0.66-7.2%$0.79$0.23▼$3.33$9.90M-0.131.49 million shs25,365 shsSURGSurgePays$0.40-11.3%$0.59$0.40▼$3.45$11.33M0.31199,944 shs377,712 shsVVOSVivos Therapeutics$0.57-6.8%$0.86$0.55▼$7.95$8.53M6.13.94 million shs279,365 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEMDAethlon Medical-5.94%-10.80%-13.24%-2.56%-90.59%ALURAllurion Technologies-9.99%-19.16%-11.11%+92.21%-73.81%SURGSurgePays-1.64%-16.64%-17.10%-48.04%-83.05%VVOSVivos Therapeutics-3.94%-11.38%-15.49%-50.51%-72.36%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEMDAethlon Medical$2.02+6.3%$2.22$1.36▼$27.40$2.98M1.491.70 million shs382,356 shsALURAllurion Technologies$0.66-7.2%$0.79$0.23▼$3.33$9.90M-0.131.49 million shs25,365 shsSURGSurgePays$0.40-11.3%$0.59$0.40▼$3.45$11.33M0.31199,944 shs377,712 shsVVOSVivos Therapeutics$0.57-6.8%$0.86$0.55▼$7.95$8.53M6.13.94 million shs279,365 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEMDAethlon Medical-5.94%-10.80%-13.24%-2.56%-90.59%ALURAllurion Technologies-9.99%-19.16%-11.11%+92.21%-73.81%SURGSurgePays-1.64%-16.64%-17.10%-48.04%-83.05%VVOSVivos Therapeutics-3.94%-11.38%-15.49%-50.51%-72.36%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEMDAethlon Medical 1.50ReduceN/AN/AALURAllurion Technologies 2.00Hold$3.00354.55% UpsideSURGSurgePays 1.67Reduce$3.50777.19% UpsideVVOSVivos Therapeutics 2.25Hold$2.80392.96% UpsideCurrent Analyst Ratings BreakdownLatest AEMD, SURG, ALUR, and VVOS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/10/2026SURGSurgePays Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.00 ➝ $3.506/4/2026VVOSVivos Therapeutics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$3.00 ➝ $3.105/22/2026SURGSurgePays Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)5/15/2026SURGSurgePays Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell4/22/2026VVOSVivos Therapeutics Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$5.50 ➝ $3.004/20/2026AEMDAethlon Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026VVOSVivos Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/17/2026SURGSurgePays Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.75 ➝ $5.004/17/2026VVOSVivos Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$7.00 ➝ $2.50(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEMDAethlon MedicalN/AN/AN/AN/A$25.52 per shareN/AALURAllurion Technologies$17.21M0.58N/AN/A($30.08) per share-0.02SURGSurgePays$62.37M0.16N/AN/A($0.66) per share-0.60VVOSVivos Therapeutics$17.44M0.45N/AN/A($0.16) per share-3.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEMDAethlon Medical-$13.39M-$14.69N/AN/AN/AN/A-219.39%-164.33%8/12/2026 (Estimated)ALURAllurion Technologies-$7.20M-$2.03N/AN/AN/A-199.96%N/A-77.13%8/18/2026 (Estimated)SURGSurgePays-$36.07M-$1.94N/A6.65N/A-64.91%-967.32%-310.16%8/12/2026 (Estimated)VVOSVivos Therapeutics-$21.17M-$2.14N/AN/AN/A-127.70%-2,325.64%-98.12%8/18/2026 (Estimated)Latest AEMD, SURG, ALUR, and VVOS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2026Q4 2025SURGSurgePays-$0.19-$0.51-$0.32-$0.51$15.50 million$15.98 million5/20/2026Q1 2026VVOSVivos Therapeutics-$0.45-$0.52-$0.07-$0.52$4.35 million$5.14 million4/15/2026Q4 2025VVOSVivos Therapeutics-$0.4950-$0.58-$0.0850-$0.58$7.10 million$3.82 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAEMDAethlon MedicalN/AN/AN/AN/AN/AALURAllurion TechnologiesN/AN/AN/AN/AN/ASURGSurgePaysN/AN/AN/AN/AN/AVVOSVivos TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEMDAethlon MedicalN/A5.685.68ALURAllurion TechnologiesN/A1.260.94SURGSurgePaysN/A0.270.26VVOSVivos Therapeutics3.310.270.27Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEMDAethlon Medical1.99%ALURAllurion Technologies21.39%SURGSurgePays6.94%VVOSVivos Therapeutics26.35%Insider OwnershipCompanyInsider OwnershipAEMDAethlon Medical0.71%ALURAllurion Technologies8.10%SURGSurgePays29.10%VVOSVivos Therapeutics2.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEMDAethlon Medical101.57 million1.56 millionNo DataALURAllurion Technologies50114.99 million11.28 millionNo DataSURGSurgePays4025.12 million17.81 millionOptionableVVOSVivos Therapeutics16013.90 million13.60 millionOptionableAEMD, SURG, ALUR, and VVOS HeadlinesRecent News About These CompaniesVivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights OfferingJune 11 at 8:30 AM | globenewswire.comVivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to ...June 10 at 9:42 AM | markets.businessinsider.comVivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular PatientsJune 10 at 9:03 AM | globenewswire.comVivos Therapeutics, Inc. to Present at The Small Cap Showcase & WTR Insights on June 9, 2026June 8, 2026 | quiverquant.comQVivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026June 8, 2026 | globenewswire.comVivos Therapeutics Announces Debt Exchange Agreement with Streeterville Capital to Strengthen Financial PositionJune 5, 2026 | quiverquant.comQVivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq ListingJune 5, 2026 | globenewswire.comVivos Therapeutics Inc (VVOS) Q1 2026 Earnings Call Highlights: Revenue Surges Amid Strategic ShiftsMay 29, 2026 | finance.yahoo.comVivos Therapeutics Balances Rapid Growth With Cash StrainMay 22, 2026 | tipranks.comVivos Therapeutics Earnings Call: Growth Meets Cash StrainMay 21, 2026 | tipranks.comVivos Therapeutics, Inc: Vivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational UpdateMay 21, 2026 | finanznachrichten.deVivos Therapeutics, Inc. (VVOS) Q1 2026 Earnings Call TranscriptMay 21, 2026 | seekingalpha.comVivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational UpdateMay 20, 2026 | globenewswire.comVivos Therapeutics Delays Quarterly FilingMay 15, 2026 | tipranks.comAnalysts see 200%+ upside in these 3 high-risk stocks: here's why?May 9, 2026 | invezz.comIVivos Therapeutics (VVOS) price target decreased by 51.67% to 2.47April 29, 2026 | msn.comVivos Therapeutics Faces Nasdaq Listing Compliance ChallengesApril 22, 2026 | tipranks.comVivos Therapeutics, Inc. (NASDAQ:VVOS) Q4 2025 Earnings Call TranscriptApril 17, 2026 | insidermonkey.comVivos Therapeutics Q4 Earnings Call HighlightsApril 17, 2026 | defenseworld.netDVivos Therapeutics Balances Growth Hopes With Cash StrainApril 16, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines2 Software Stocks Turning AI Fears Into Fundamental GainsBy Dan Schmidt | May 21, 2026As Broadcom Eclipses $2 Trillion, Private Credit Giants Wants InBy Leo Miller | May 17, 2026The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in FocusBy Jeffrey Neal Johnson | June 4, 2026CAVA Group’s Stock Looks Delicious After Strong EarningsBy Chris Markoch | May 22, 2026Palantir’s Drone Tailwind Puts Its Defense AI Story Back in Focus for InvestorsBy Chris Markoch | June 2, 2026AEMD, SURG, ALUR, and VVOS Company DescriptionsAethlon Medical NASDAQ:AEMD$2.02 +0.12 (+6.32%) Closing price 04:00 PM EasternExtended Trading$2.03 +0.01 (+0.64%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation. The company was incorporated in 1999 and is based in San Diego, California.Allurion Technologies NYSE:ALUR$0.66 -0.05 (-7.17%) As of 03:49 PM EasternAllurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.SurgePays NASDAQ:SURG$0.40 -0.05 (-11.33%) Closing price 04:00 PM EasternExtended Trading$0.42 +0.02 (+5.28%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SurgePays, Inc., together with its subsidiaries, operates as a financial technology and telecom company in the United States. It operates through three segments: Mobile Virtual Network Operators, Comprehensive Platform Services, and Lead Generation. The company offers subsidized and non-subsidized mobile virtual network operators for internet connectivity through mobile broadband services to consumers; ACH banking relationships and fintech transactions platform to convenience stores; wireless top-up transactions and wireless product aggregation; and lead generation and case management solutions primarily to law firms in the mass tort industry, as well as call center activities. SurgePays, Inc. is headquartered in Bartlett, Tennessee.Vivos Therapeutics NASDAQ:VVOS$0.57 -0.04 (-6.79%) Closing price 04:00 PM EasternExtended Trading$0.57 -0.01 (-0.87%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Vivos Therapeutics, Inc., a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. Vivos Therapeutics, Inc. was founded in 2016 and is based in Littleton, Colorado. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
